Ohuchi Kazuki, Kurita Hisaka, Murakami Takanori, Takizawa Shinnosuke, Fujimaki Ayaka, Murata Junya, Oida Yasuhisa, Hozumi Isao, Kitaichi Kiyoyuki, Inden Masatoshi
Laboratory of Medical Therapeutics and Molecular Therapeutics, Japan; Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan.
Laboratory of Medical Therapeutics and Molecular Therapeutics, Japan.
Biochem Biophys Res Commun. 2025 Jan;743:151181. doi: 10.1016/j.bbrc.2024.151181. Epub 2024 Dec 13.
A GGGGCC hexanucleotide repeat expansion (HRE) within the C9orf72 gene is a major causative factor in amyotrophic lateral sclerosis (ALS). This aberrant HRE results in the generation of five distinct dipeptide repeat proteins (DPRs). Among the DPRs, poly-PR accumulates in the nucleus and exhibits particularly strong toxicity to motor and cortical neurons. Fibroblast growth factor receptor 1 (FGFR1) is known to promote neurogenesis and inhibit apoptosis in neurons. Nevertheless, there has been no previous report of its neuroprotective effects against poly-PR toxicity. The objective of this study was to investigate the neuroprotective effects of FGFR1 activation in poly-PR-expressing NSC34 motor neuron-like cells. RT-qPCR analysis in NSC34 cells showed that Fgfr1 was the most highly expressed member of the Fgfr family in NSC34 cells. The activation of FGFR1 by FGF2, a common ligand for all FGFRs, exerted neuroprotective effects against the toxicity of poly-PR. Additionally, FGFR1 activation was observed to enhance cell viability through the PI3K-AKT pathway, while the contribution of the MEK-ERK pathway was found to be limited. Furthermore, FGFR1 activation suppressed the accumulation of p53 protein and promoted its degradation through increased murine double minute 2 (MDM2), an E3 ubiquitin ligase that targets p53. The neuroprotective effects were attenuated by PD173074, a selective FGFR1 inhibitor or Nutlin-3a, an inhibitor of the p53-MDM2 interaction. Overall, these findings suggest that FGFR1 activation provides neuroprotection against poly-PR toxicity. Consequently, this study suggests the potential utility of FGFR1 activation as a therapeutic strategy for ALS.
C9orf72基因内的GGGGCC六核苷酸重复扩增(HRE)是肌萎缩侧索硬化症(ALS)的主要致病因素。这种异常的HRE导致产生五种不同的二肽重复蛋白(DPR)。在这些DPR中,聚脯氨酸-精氨酸(poly-PR)在细胞核中积累,对运动神经元和皮质神经元表现出特别强的毒性。成纤维细胞生长因子受体1(FGFR1)已知可促进神经发生并抑制神经元凋亡。然而,此前尚无关于其对poly-PR毒性的神经保护作用的报道。本研究的目的是研究FGFR1激活在表达poly-PR的NSC34运动神经元样细胞中的神经保护作用。对NSC34细胞进行的RT-qPCR分析表明,Fgfr1是NSC34细胞中Fgfr家族中表达最高的成员。所有FGFR的常见配体FGF2对FGFR1的激活对poly-PR的毒性发挥了神经保护作用。此外,观察到FGFR1激活通过PI3K-AKT途径增强细胞活力,而MEK-ERK途径的作用有限。此外,FGFR1激活抑制了p53蛋白的积累,并通过增加鼠双微体2(MDM2,一种靶向p53的E3泛素连接酶)促进其降解。选择性FGFR1抑制剂PD173074或p53-MDM2相互作用抑制剂Nutlin-3a减弱了神经保护作用。总体而言,这些发现表明FGFR1激活可提供针对poly-PR毒性的神经保护。因此,本研究表明FGFR1激活作为ALS治疗策略的潜在效用。